Cartilage regeneration procedures rebuild focal cartilage defects using the patient's own cultured chondrocytes or allogeneic umbilical cord blood derived cells, an option approved and used in Korea before most other markets.
0 listed clinics · Updated 2026-08-09

Korea approved Cartistem, an allogeneic umbilical cord blood derived stem cell product for knee cartilage, in 2012, and it remains one of the few such products with regulatory approval anywhere. Autologous chondrocyte implantation requires two operations separated by several weeks for cell culture.
These treatments target focal defects in relatively young patients. They are not a substitute for joint replacement in established diffuse osteoarthritis, and any clinic suggesting otherwise is overselling.
No. Approved cartilage regeneration products treat focal cartilage defects, generally in patients under about 60 with otherwise sound joint alignment. Diffuse advanced osteoarthritis is not an indication.
Allogeneic products can be done in one operation. Autologous chondrocyte implantation needs two procedures separated by three to six weeks of cell culture, so either a long stay or two trips.
Total knee replacement resurfaces the damaged joint with metal and polyethylene components, and Korean centers...
Endoscopic spine surgery removes a herniated disc fragment through an incision under one centimetre using a wo...
Arthroscopic rotator cuff repair reattaches torn tendon to bone with suture anchors through several small port...
The length of your trip is set by the mandatory follow-up interval, not by how quickly you feel well, and flying too early raises the risk of swelling, bleeding and thrombosis.
Foreign patients without Korean national health insurance pay the full private rate, which is still typically 30 to 70 percent below US pricing for the same procedure, and card payment is accepted almost everywhere.
Source: Ministry of Food and Drug Safety, Republic of Korea https://www.mfds.go.kr/eng/index.do